Ceribell, Inc. (NASDAQ: CBLL) President and CEO Chao Xingjuan executed a series of transactions on July 7, 2026, selling 39,000 shares of the company's common stock through a Rule 10b5-1 trading plan. The sale generated approximately $776,100 at a weighted average price of $19.90 per share. Concurrently, Ms. Chao exercised stock options to acquire 25,000 shares at an exercise price of $4.70. These transactions occurred alongside the company's recent Q1 2026 earnings report, which highlighted significant revenue growth but also a wider-than-expected loss per share.
The shares were sold at a weighted average price of $19.90, with individual transaction prices ranging from $19.69 to $20.27. The stock currently trades at $19.44, and according to InvestingPro analysis, appears overvalued at current levels, placing it among companies on the most overvalued list.
The transactions were executed pursuant to a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying or selling shares to avoid accusations of trading on inside information.
On the same day, Ms. Chao also acquired 25,000 shares of Ceribell common stock through the exercise of stock options. These shares were acquired at an exercise price of $4.70 per share, amounting to a total value of $117,500. Of these options, 1,446 shares were from an option that vests monthly from April 1, 2023, while the remaining 23,554 shares were from a fully vested and currently exercisable stock option.
Following these transactions, Ms. Chao directly holds 802,317 shares of Ceribell common stock. Additionally, she holds an indirect beneficial interest in 369,088 shares through the ACP 2021 Trust, where she serves as a co-trustee. Ms. Chao disclaims beneficial ownership of these indirectly held securities except to the extent of her pecuniary interest. The company, valued at $736 million, posted revenue growth of 33% while maintaining an impressive gross profit margin of 88%. For deeper insights into Ceribell's financial health and access to exclusive Pro Research Reports covering 1,400+ US stocks, visit InvestingPro.CeriBellFollowAnalyze CBLLIncluded in our AI-picked strategies·Review strategies19.44▲+0.04(+0.21%)Real-time Data·12:37:12·USD1D1W1M6M1Y5YMaxCreated with Highcharts 11.4.818:0019:0009/0715:0016:0019.219.319.419.5Analyze CBLLIn other recent news, Ceribell reported its first-quarter 2026 earnings, showing a significant revenue increase despite a wider-than-expected loss per share. The company's revenue rose by 29% year-over-year to $26.5 million, surpassing both Canaccord's estimate of $25.9 million and the consensus of $26.1 million. However, Ceribell's earnings per share (EPS) reported a loss of $0.52, which was greater than the anticipated loss of $0.36. Following these results, Ceribell adjusted its full-year revenue guidance to $114 million at the midpoint, slightly up from $113 million.
In response to these developments, Canaccord maintained its Buy rating on Ceribell but lowered the stock's price target from $28 to $25, citing valuation compression. This adjustment reflects Canaccord's analysis of the company's financial performance and market conditions. These recent developments highlight Ceribell's robust revenue growth and the challenges it faces in meeting earnings expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Is your CBLL trade worth the risk?Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your CBLL chart and delivers a complete risk management plan—entry, stop-loss, and profit target—in under 60 seconds.Protect your downside. Validate every trade. Invest smarter.July Sale - 60% Off InvestingPro